Sulfur hexafluoride

Drug Profile

Sulfur hexafluoride

Alternative Names: BRI; E-7210; Lumason; SonoVue; sulfur hexafluoride lipid-type A microspheres; Sulphur hexafluoride

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Bracco
  • Developer Bracco; Eisai Co Ltd
  • Class Contrast media; Fluorides; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebrovascular disorders
  • Registered Cardiovascular disorders; Liver disorders; Vesicoureteral reflux
  • Phase III Congenital heart defects; Coronary artery disease

Most Recent Events

  • 12 Jan 2017 Registered for Vesicoureteral reflux (Diagnosis, In children, In infants, In neonates, In adolescents) in USA (IV)
  • 04 Apr 2016 Registered for Liver disorders (Diagnosis, In adults, In children) in USA (IV)
  • 15 Sep 2015 Bracco Diagnostics plans a phase III trial for Coronary artery disease (Diagnosis) in USA and Canada (NCT02552238)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top